This result, again, matches what is currently known in ERBB2-mutant gastric cancers and other cancers such as breast and lung cancers: overexpression of ERBB2 promotes tumor growth and survival by downstream signaling through the PI3K-AKT and RAS-MAPK pathways. The gene discussed is AKT1; the disease is cancer.